OKLAHOMA CITY, Aug. 14, 2007 (PRIME NEWSWIRE) -- AMS Health Sciences, Inc. (AMEX:AMM) today reported results for its second quarter ended June 30, 2007, reflecting a transition period focused on corporate restructuring initiatives to support a return to profitability.
Net loss for the quarter was $320,674, or $0.04 per share, compared with a net loss of $70,000, or $0.01 per share, a year earlier -- based upon a 13.5 percent increase in the number of basic shares outstanding for the 2007 second quarter. Net sales for the quarter were $1,979,288 compared with $2,480,875 a year ago.
For the six-month period, the company reported a net loss of $731,013, or $0.08 per share, compared with a net loss of $312,554, or $0.04 per share, last year -- based on a 12.9 percent increase in the number of basic shares outstanding. Net sales for the six months were $4,414,630 compared with $4,906,349 for the same period in 2006.
"The company has made significant progress in its strategic initiatives to support sustainable growth and profitability. Our team is extremely focused on executing aggressive sales and marketing campaigns to increase recruiting -- supported, in part, by tremendous consumer interest in the company's new Saba Life product line and innovative pouch packaging," said Jerry Grizzle, Ph.D., president and chief executive officer.
Based on current recruiting and sales trends, Grizzle expressed optimism that the company would be able to achieve a monthly sales level of at least $1.0 million -- a level that management believes will support a return to operational profitability. Grizzle added that, based on recruitment levels for July, the company expects to achieve average recruitment increases of between 10 to 25 percent per month through the balance of 2007.
He noted that opening orders from new associates for the quarter averaged $261.62 compared with $90.73 for the same period a year earlier. Grizzle attributed this increase, in part, to consumer interest in the company's Saba product line, particularly its new advanced natural weight loss formula incorporating the Borojo fruit from the Amazon.
About AMS Health Sciences
AMS Health Sciences, Inc. develops and distributes nutritional, weight loss, and personal care products -- including antioxidants, pomegranate-based supplements, a proprietary blend of adaptogenic herbs developed by the late Dr. Israel Brekhman, minerals, vitamins and other nutritional supplements. Its products are sold through a network marketing system utilizing independent distributors in the United States, Puerto Rico, and Canada. Founded in 1988, the company is based in Oklahoma City, Oklahoma. Additional information is available at www.amsonline.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the Company's current expectations and beliefs, including, among other things: (i) expectations regarding the positive impact of certain strategic initiatives to contain costs and increase sales; and (ii) our plans regarding the rollout of our new Saba product line. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to: (a) material decreases in active distributors, or the Company's failure to execute its strategic initiatives; (b) regulatory risks associated with the Company's nutritional supplements, which could adversely affect the Company if regulatory scrutiny dampens enthusiasm or the ability of the Company or its distributors to effectively market its products; (c) any failure of current or planned initiatives or products, including, among others, the introduction of the Saba line of nutritional supplements, to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis; (d) any inability of the Company to obtain necessary product registrations for its nutritional and personal care products in a timely manner; (e) adverse publicity related to the Company's business, products or industry; and (f) continued competitive pressures in the Company's markets. The Company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB. The forward-looking statements set forth the Company's beliefs as of the date of this release, and the Company assumes no duty to update the forward-looking statements contained in this release to reflect any change.
AMS HEALTH SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
----------- ----------- ----------- -----------
Net sales $ 1,979,288 $ 2,480,875 $ 4,414,630 $ 4,906,349
----------- ----------- ----------- -----------
Cost of sales:
Cost of product 509,646 754,902 1,261,406 1,492,241
Associate
commissions 590,627 732,583 1,395,572 1,560,398
----------- ----------- ----------- -----------
Total cost of
sales 1,100,273 1,487,485 2,656,978 3,052,639
----------- ----------- ----------- -----------
Gross profit 879,015 993,390 1,757,652 1,853,710
Marketing and
administrative
expenses:
Marketing 99,531 101,851 382,527 242,995
Administrative 916,440 765,564 1,813,905 1,455,084
----------- ----------- ----------- -----------
Total marketing
and
administrative
expenses 1,015,971 867,415 2,196,432 1,698,079
----------- ----------- ----------- -----------
Income (loss)
from
operations (136,956) 125,975 (438,780) 155,631
Other income
(expense):
Interest and
dividends, net (175,814) 5,246 (318,988) 9,088
Other, net 12,187 (15,704) 39,192 43,959
----------- ----------- ----------- -----------
Total other
income (expense) (163,627) (10,458) (279,796) 53,047
----------- ----------- ----------- -----------
Income (loss)
from
continuing
operations before
taxes (300,583) 115,517 (718,576) 208,678
Income tax
expense (benefit) -- -- -- --
----------- ----------- ----------- -----------
Income (loss) from
continuing
operations (300,583) 115,517 (718,576) 208,678
Discontinued
operations
(Note 13)
Income (loss) from
discontinued
operations, net of
tax (20,091) (185,517) (12,437) (521,232)
----------- ----------- ----------- -----------
Net loss ($ 320,674) ($ 70,000) ($ 731,013) ($ 312,554)
=========== =========== =========== ===========
Net loss per share:
Basic:
Income (loss) from
continuing
operations ($ 0.04) $ 0.01 ($ 0.08) $ 0.03
Income (loss)
from
discontinued
operations net of
tax -- (0.02) -- (0.07)
----------- ----------- ----------- -----------
Net loss per
share ($ 0.04) ($ 0.01) ($ 0.08) ($ 0.04)
=========== =========== =========== ===========
Diluted:
Income (loss) from
continuing
operations ($ 0.04) $ 0.01 ($ 0.08) $ 0.03
Income (loss) from
discontinued
operations net
of tax -- (0.02) -- (0.07)
----------- ----------- ----------- -----------
Net loss per
share ($ 0.04) ($ 0.01) ($ 0.08) ($ 0.04)
=========== =========== =========== ===========
Shares used in
computing net loss
per share:
Basic 8,562,113 7,545,708 8,515,824 7,545,708
=========== =========== =========== ===========
Diluted 8,562,113 7,547,324 8,515,824 7,555,868
=========== =========== =========== ===========
AMS HEALTH SCIENCES, INC.
CONSOLIDATED BALANCE SHEET
June 30, December 31,
ASSETS 2007 2006
----------------------------------------- ------------ ------------
(Unaudited)
CURRENT ASSETS:
Cash $ 285,977 $ 269,726
Marketable securities, available for
sale, at fair value -- 793,183
Receivables 14,577 44,576
Inventory, net 655,470 700,664
Other assets 76,083 77,319
Current assets of discontinued operations 2,139 110,521
------------ ------------
Total current assets 1,034,246 1,995,989
RESTRICTED SECURITIES 80,565 78,723
RECEIVABLES 26,134 28,374
PROPERTY AND EQUIPMENT, net 2,556,231 2,794,393
COVENANTS NOT TO COMPETE and other
intangibles, net 285,645 324,553
OTHER ASSETS 370,985 457,344
NONCURRENT ASSETS OF DISCONTINUED
OPERATIONS 1,176,841 1,253,480
------------ ------------
TOTAL $ 5,530,647 $ 6,932,856
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
-----------------------------------------
CURRENT LIABILITIES:
Accounts payable $ 80,652 $ 559,920
Accrued commissions and bonuses 261,426 268,717
Accrued other expenses 272,983 400,204
Accrued sales tax liability 224,418 200,481
Deferred compensation 97,889 96,378
Notes payable 757,542 257,542
Capital lease obligations 95,404 104,591
Current liabilities of discontinued
operations 313,116 360,582
------------ ------------
Total current liabilities 2,103,430 2,248,415
LONG-TERM LIABILITIES:
Notes payable 355,012 625,220
Capital lease obligations 45,514 95,527
Deferred compensation 236,566 281,101
Lease abandonment liability 4,059 55,123
Liabilities of discontinued operations 1,416,519 1,570,359
------------ ------------
Total liabilities 4,161,100 4,875,745
------------ ------------
COMMITMENT AND CONTINGENCIES (Note 8)
STOCKHOLDERS' EQUITY
Common stock - $.0001 par value;
authorized 495,000,000 shares; issued
9,107,419 and 9,107,419 shares;
outstanding 8,515,824 and 8,515,824
shares, respectively 905 905
Paid-in capital 23,653,311 23,609,734
Notes receivable for exercise of options (31,000) (31,000)
Accumulated deficit (19,620,890) (18,889,749)
------------ ------------
Total capital and accumulated deficit 4,002,326 4,689,890
Less cost of treasury stock (591,595
shares) (2,632,779) (2,632,779)
------------ ------------
Total stockholders' equity 1,369,547 2,057,111
------------ ------------
TOTAL $ 5,530,647 $ 6,932,856
============ ============